, Volume 118, Issue 3, pp 501-555
Date: 17 Apr 2014

The role of cytotoxic chemotherapy in the management of progressive glioblastoma

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access



What is the impact of cytotoxic chemotherapy on disease control and survival in the adult patient with progressive glioblastoma?

Target population

This recommendation applies to adults patients with progressive glioblastoma.


Level II

Temozolomide is recommended as superior to procarbazine in patients with first relapse of glioblastoma after having received nitrosourea chemotherapy or no prior cytotoxic chemotherapy at the time of initial therapy.

The use of BCNU-impregnated biodegradable polymer wafers is recommended in the management of progressive glioblastoma as a surgical adjunct when cytoreductive surgery is indicated, taking into account the associated toxicities seen with this modality.

Level III

Consideration of a variety of cytotoxic chemotherapy agents of uncertain benefit is recommended in the setting of progressive glioblastoma based on the judgment of the treating physician taking into account the individual patients prior treatment exposure, systemic health, and likelihood of tolerance of the toxicities of any given agent. It is recommended in such cases that enrollment in available clinical trials be encouraged.